Literature DB >> 22262993

Palliative Hypofractionated Radiotherapy For Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy: Is It For Many, Some, All, Or None?

Timothy D Wagner1.   

Abstract

Entities:  

Year:  2009        PMID： 22262993      PMCID： PMC3256483     

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC): effective palliation and patients' convenience.

Authors:  G A Plataniotis; J R Kouvaris; C Dardoufas; V Kouloulias; M A Theofanopoulou; L Vlahos
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

3.  Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

Authors:  F R Macbeth; J J Bolger; P Hopwood; N M Bleehen; J Cartmell; D J Girling; D Machin; R J Stephens; A J Bailey
Journal:  Clin Oncol (R Coll Radiol)       Date:  1996       Impact factor: 4.126

4.  Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy.

Authors:  George A Plataniotis; Maria-Aikaterini Theofanopoulou; Konstantinia Sotiriadou; Kyriaki Theodorou; Panagiotis Mavroidis; George Kyrgias
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

5.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

Authors:  R O Dillman; J Herndon; S L Seagren; W L Eaton; M R Green
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

6.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

Review 7.  The clinical implementation of respiratory-gated intensity-modulated radiotherapy.

Authors:  Paul Keall; Sastry Vedam; Rohini George; Chris Bartee; Jeffrey Siebers; Fritz Lerma; Elisabeth Weiss; Theodore Chung
Journal:  Med Dosim       Date:  2006       Impact factor: 1.482

Review 8.  Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.

Authors:  Carrie B Lee; Thomas E Stinchcombe; Julian G Rosenman; Mark A Socinski
Journal:  Clin Lung Cancer       Date:  2006-11       Impact factor: 4.785

9.  Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

Authors:  Kathy S Albain; John J Crowley; Andrew T Turrisi; David R Gandara; William B Farrar; Joseph I Clark; Kristie R Beasley; Robert B Livingston
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

Review 10.  Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer.

Authors:  Chaundré K Cross; Stuart Berman; Lori Buswell; Bruce Johnson; Elizabeth H Baldini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.